Onco-Innovations Ltd. is a Canadian biotech company, which engages in cancer research and treatment, specializing in oncology. The company is headquartered in Calgary, Alberta. The company went IPO on 2024-11-27. The firm holds an exclusive worldwide license to patented technology that targets solid tumors. The firm is engaged in developing and commercializing treatments for various types of cancer. Its solution focuses on targeting cancer cells, effectively eliminating them and preventing their regrowth. Its licensed technology focuses on Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitors. Its SynoGraph platform merges genomic, proteomic, and multimodal datasets to uncover deep insights into disease mechanisms, potentially enabling more personalized and effective treatment strategies.
